RWLK REWALK ROBOTICS LTD

ReWalk Robotics to Report Fourth Quarter and Year-End 2019 Financial Results on February 20, 2020

ReWalk Robotics to Report Fourth Quarter and Year-End 2019 Financial Results on February 20, 2020

MARLBOROUGH, Mass., BERLIN and YOKNEAM ILIT, Israel, Feb. 17, 2020 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter and year-end 2019 financial results on Thursday, February 20, 2020, before the U.S. financial markets open.   

Larry Jasinski, Chief Executive Officer, and Ori Gon, Chief Financial Officer, will host a conference call to discuss the results as follows:

Time8:30 A.M EST
Toll free (U.S.)(844) 423-9889
International (U.S)(716) 247-5804
Germany08 00 18 15 287
Israel18 09 31 53 62
Access Code7697891
Webcast (live and replay) 



under the ‘Investors’ section'.

The archived webcast will be available via the following URL or through the 'Investors' section' on . 

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.  ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit .

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States. 

Investor Contact:

Ori Gon

Chief Financial Officer 

ReWalk Robotics Ltd.

T:  

E: 

EN
17/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

 PRESS RELEASE

Lifeward Expands International Distribution of its ReWalk® Personal Ro...

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable...

 PRESS RELEASE

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic...

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for  of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBORO...

 PRESS RELEASE

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Ap...

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received it...

 PRESS RELEASE

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Lifeward Ltd. Reports Third Quarter 2025 Financial Results Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch